Cargando…

Establishment of a prospective multicenter cohort for advanced non‐small cell lung cancer in China (CAPTRA‐Lung study)

The CAPTRA‐Lung study (NCT03334864) is a prospective observational study that will capture real‐world data of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) across China. The study aims to complement the results from current therapeutic regimens to improve the standard of di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yan, Zhang, Li, Fang, Jian, Wang, Ziping, Li, Junling, Li, Lin, Ai, Bin, Nie, Ligong, Mu, Xinlin, Liang, Li, Zhang, Shucai, Zhang, Yuhui, Song, Yuguang, Song, Xia, Wang, Ye, Xin, Tao, Jin, Bo, Wang, Xiaohong, Ding, Cuimin, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Study Protocols
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275840/ https://www.ncbi.nlm.nih.gov/pubmed/30264504 http://dx.doi.org/10.1111/1759-7714.12865

Ejemplares similares

Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross‐sectional study
por: Zhang, Bo, et al.
Publicado: (2022)

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
por: Liang, Hongge, et al.
Publicado: (2019)

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
por: Shi, Yuankai, et al.
Publicado: (2015)

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
por: Xing, Puyuan, et al.
Publicado: (2019)

The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China
por: Yi, Jiawen, et al.
Publicado: (2022)

Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China
por: He, Xiaoning, et al.
Publicado: (2021)

ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma
por: Wang, Zheng, et al.
Publicado: (2016)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
por: Liu, Yutao, et al.
Publicado: (2017)

Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer
por: Wang, Jingjing, et al.
Publicado: (2016)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients
por: Zhuo, Minglei, et al.
Publicado: (2020)

Histologic transformation of lung cancer during pembrolizumab therapy: A case report
por: Si, Xiaoyan, et al.
Publicado: (2020)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
por: Wang, Hanping, et al.
Publicado: (2018)

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status
por: Wei, Zhong, et al.
Publicado: (2008)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

A miR-SNP of the XPO5 gene is associated with advanced non-small-cell lung cancer
por: Ding, Cuimin, et al.
Publicado: (2013)

A Clinical Risk Model to Predict Rapidly Progressive Interstitial Lung Disease Incidence in Dermatomyositis
por: Li, Yimin, et al.
Publicado: (2021)

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
por: Shi, Yuequan, et al.
Publicado: (2021)

Establishment of a Rat Adjuvant Arthritis-Interstitial Lung Disease Model
por: Song, Liu-nan, et al.
Publicado: (2016)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study
por: Jiang, Yanan, et al.
Publicado: (2018)

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Improvements of the Surgical Technique on the Established Mouse Model of Orthotopic Single Lung Transplantation
por: Zheng, Zhikun, et al.
Publicado: (2013)

Identification of Key Genes in Lung Adenocarcinoma and Establishment of Prognostic Mode
por: Jiawei, Zhou, et al.
Publicado: (2020)

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer
por: Liu, Ziwei, et al.
Publicado: (2020)

Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study
por: Cheng, Ying, et al.
Publicado: (2018)

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
por: Lu, Shun, et al.
Publicado: (2022)

PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer
por: Gao, Xiang, et al.
Publicado: (2023)

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
por: Shi, Yuankai, et al.
Publicado: (2023)

Pembrolizumab and chemotherapy in non‐small cell lung cancer with EGFR ex20ins mutation: A case report
por: Zhang, Meng, et al.
Publicado: (2021)

Research on Operation Efficiency and Membrane Fouling of A(2)/O-MBR in Reclaimed Water Treatment
por: Li, Fenfen, et al.
Publicado: (2019)

The Prevalence and clinical characteristics of primary Sjogren’s syndrome patients with lung cancer: An analysis of ten cases in China and literature review
por: Xu, Yan, et al.
Publicado: (2015)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020)

A rapid liquid biopsy of lung cancer by separation and detection of exfoliated tumor cells from bronchoalveolar lavage fluid with a dual-layer “PERFECT” filter system
por: Li, Tingyu, et al.
Publicado: (2020)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
por: Mu, Yuxin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6jnqgib1h6tmnp84tm6qsfnsl6